Understanding the role of B cells in cancer through antibody repertoire analysis

Join industry experts Dr. Dmitriy M. Chudakov, CSO at MiLaboratory LLC, and Dr. Nicola Bonzanni, CSO at ENPICOM, for an in-depth discussion on what we can learn from B cells and antibody repertoires to advance cell and gene therapies. Discover recent advancements in B cell research and cutting-edge software solutions for analyzing antibody repertoires.

What will you learn?

There is significant interest in the role of B cells in cancer. With an increasing demand for antibody and cell-based therapeutics, a deeper understanding of the immune system and cancer genomics has become more crucial than ever. By studying B cells and immune repertoires, researchers are able to discover more nuanced and targeted therapies against cancer. In this webinar, we will discuss:

  • Roles of B cells in cancer
  • The use of antibody repertoires in tumor samples
  • How to address challenges of intratumoral clonal heterogeneity
  • The use of cutting-edge technologies to leverage the full potential of antibody sequencing data
On-demand webinar ENPICOM
Meet the speakers:

Dr. Chudakov’s work focuses on clonal T cell and B cell populations in autoimmunity and cancer, DNA technologies, and software development for quantitative analysis of TCR and antibody repertoires. In addition to leading adaptive immunity research in some of the biggest universities in Russia and Czech Republic, Dr. Dmitriy M. Chudakov serves an Associate Prof. at Skolkovo Institute of Science and Technology (Moscow, Russia) where he studies the basics of adaptive immunity in health and disease.


As Chief Scientific Officer at ENPICOM, Dr. Bonzanni uses his passion for science and technology to close the gap between life sciences, software engineering, and data visualization to empower life scientists with state-of-the-art computational software solutions. He manages the scientific team with bioinformaticians, computational immunologists, scientific project managers, and product managers.